Background Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal
fibrosis, but they often have substantial toxic effects. Several reports have suggested …

BACKGROUND: Tamoxifen may be a viable treatment option for idiopathic retroperitoneal
fibrosis (iRPF) but data are limited and its long-term safety and efficacy is unclear. We …

Background: Small case series suggest that a combination of mycophenolate mofetil and
prednisone may be an effective treatment for patients with retroperitoneal fibrosis. Objective …

BACKGROUND: Primary medical treatment of idiopathic retroperitoneal fibrosis (RPF)
increasingly is accepted. However, the optimum treatment strategy is still unclear. STUDY …

OBJECTIVE To describe the clinical manifestations, laboratory results, imaging findings, and
treatments in patients with idiopathic retroperitoneal fibrosis (IRF) seen at Mayo Clinic in …

Background: Anecdotal case reports suggest tamoxifen as a possible treatment for
retroperitoneal fibrosis, but a systematic assessment of its effect is not available. Objective …

OBJECTIVE: To evaluate the value of 18F-fluorodeoxyglucose positron emission
tomography (FDG-PET) in monitoring disease activity and predicting treatment response in …

Retroperitoneal fibrosis (RF) is a disease that can occur at any age, with a peak incidence in
patients 40 to 60 years of age. The characteristic finding in this disease is a periaortic fibrous …

Prompt diagnosis of idiopathic retroperitoneal fibrosis improves chances of preserving renal
function, preventing involvement of other organs, and relieving symptoms. Computed …

Methods We reviewed the clinical records of patients admitted to our hospital for
retroperitoneal fibrosis between January 1990 and January 2002. Twenty-six patients (19 …